RecruitingNCT06221358

Pharmacogenomics of Stimulant Treatment Response

Pharmacogenomics of Stimulant Treatment Response in Children and Adolescents With Attention-Deficit/ Hyperactivity Disorder

Sponsor

University of Calgary

Enrollment

400 participants

Start Date

Apr 1, 2024

Study Type

OBSERVATIONAL

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Summary

The "Pharmacogenomics of Stimulant Treatment Response" (PGx-STaR) study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-24 with Attention deficit/hyperactivity disorder (ADHD).

Eligibility

Min Age: 6 YearsMax Age: 24 Years

Inclusion Criteria5

Patients will be eligible for participation if all the following are true.
Aged 6 - 24 years.
Located in Western Canada (i.e., Alberta, British Columbia, Saskatchewan, Manitoba).
Primary diagnosis of ADHD (all types).
Starting Methylphenidate (excluding immediate release forms) treatment.

Exclusion Criteria7

Patients will be excluded from participation if any of the following are true.
Co-occurring psychotic, bipolar or eating disorders.
Significant risk of suicide.
An intellectual disability, or diagnosis of autism spectrum disorder (ASD) or tics/Tourette disorders.
Past 12-month high-risk alcohol or substance use defined as monthly or more frequent use.
Psychotherapy or brain stimulation-based therapy initiated within 8 weeks of referral or plans to initiate/change these types of therapies during the study
History of liver or bone marrow (hematopoietic cell) transplant as these events can result in ambiguous genomic results.